Low Tumor-to-Stroma Ratio Reflects Protective Role of Stroma against Prostate Cancer Progression
Abstract
:1. Introduction
2. Results
2.1. TSR Evaluation in the Pilot and Validation Cohort
2.2. Clinical Significance of TSR in the Pilot Cohort
2.3. Clinical Significance of TSR in the Validation Cohort
2.4. RNA Expression Characteristics in Relation to the TSR Score
3. Discussion
4. Material and Methods
4.1. Pilot Study to Test Feasibility of Quantification Method
4.2. Patient Characteristics of Validation Cohort
4.3. Immunohistochemistry for EpCAM and Different Markers Associated with Tumor Cells
4.4. Evaluation of TSR
4.5. RNA Extraction
4.6. nCounter Gene Expression Assay
4.7. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Culp, M.B.; Soerjomataram, I.; Efstathiou, J.A.; Bray, F.; Jemal, A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur. Urol. 2019, 77, 38–52. [Google Scholar] [CrossRef]
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferrer-Batallé, M.; Llop, E.; Ramírez, M.; Aleixandre, R.N.; Saez, M.; Comet, J.; de Llorens, R.; Peracaula, R. Comparative study of blood-based biomarkers, α2,3-sialic acid PSA and PHI, for high-risk prostate cancer detection. Int. J. Mol. Sci. 2017, 18, 845. [Google Scholar] [CrossRef] [PubMed]
- Tyekucheva, S.; Bowden, M.; Bango, C.; Giunchi, F.; Huang, Y.; Zhou, C.H.; Bondi, A.; Lis, R.; Van Hemelrijck, M.; Andrén, O.; et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat. Commun. 2017, 8, 420. [Google Scholar] [CrossRef] [Green Version]
- Taylor, R.; Risbridger, G. Prostatic Tumor Stroma: A Key Player in Cancer Progression. Curr. Cancer Drug Targets 2008, 8, 490–497. [Google Scholar] [CrossRef] [PubMed]
- Chung, L.W.K.; Baseman, A.; Assikis, V.; Zhau, H.E. Molecular insights into prostate cancer progression: The missing link of tumor microenvironment. J. Urol. 2005, 173, 10–20. [Google Scholar] [CrossRef] [PubMed]
- Valkenburg, K.C.; de Groot, A.E.; Pienta, K.J. Targeting the tumour stroma to improve cancer therapy. Nat. Rev. Clin. Oncol. 2018, 15, 366–381. [Google Scholar] [CrossRef]
- Levesque, C.h.; Nelson, P.S. Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. Cold Spring Harb. Perspect. Med. 2019, 8, a030510. [Google Scholar] [CrossRef] [PubMed]
- Kemi, N.; Eskuri, M.; Herva, A.; Leppänen, J.; Huhta, H.; Helminen, O.; Saarnio, J.; Karttunen, T.J.; Kauppila, J.H. Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Br. J. Cancer 2018, 119, 435–439. [Google Scholar] [CrossRef] [Green Version]
- Kemi, N.; Eskuri, M.; Kauppila, J.H. Tumour-stroma ratio and 5-year mortality in gastric adenocarcinoma: A systematic review and meta-analysis. Sci. Rep. 2019, 9, 16018. [Google Scholar] [CrossRef] [Green Version]
- Smit, M.; van Pelt, G.; Roodvoets, A.; Meershoek-Klein Kranenbarg, E.; Putter, H.; Tollenaar, R.; van Krieken, J.H.; Mesker, W. Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study. JMIR Res. Protoc. 2019, 8, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Aurello, P.; Berardi, G.; Giulitti, D.; Palumbo, A.; Tierno, S.M.; Nigri, G.; D’Angelo, F.; Pilozzi, E.; Ramacciato, G. Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients. Surgeon 2017, 15, 329–335. [Google Scholar] [CrossRef] [PubMed]
- Ersvær, E.; Hveem, T.S.; Vlatkovic, L.; Brennhovd, B.; Kleppe, A.; Tobin, K.A.R.; Pradhan, M.; Cyll, K.; Wæhre, H.; Kerr, D.J.; et al. Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer. Int. J. Cancer 2020, 147, 1228–1234. [Google Scholar] [CrossRef] [Green Version]
- Geessink, O.G.F.; Baidoshvili, A.; Klaase, J.M.; Bejnordi, B.E.; Litjens, G.J.S.; van Pelt, G.W.; Mesker, W.E.; Nagtegaal, I.D.; Ciompi, F.; van der Laak, J.A.W.M. Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. Cell Oncol. 2019, 42, 331–341. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van Pelt, G.W.; Sandberg, T.P.; Morreau, H.; Gelderblom, H.; van Krieken, J.H.J.M.; Tollenaar, R.A.E.M.; Mesker, W.E. The tumour–stroma ratio in colon cancer: The biological role and its prognostic impact. Histopathology 2018, 73, 197–206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van Pelt, G.W.; Kjær-Frifeldt, S.; van Krieken, J.H.J.M.; Al Dieri, R.; Morreau, H.; Tollenaar, R.A.E.M.; Sørensen, F.B.; Mesker, W.E. Scoring the tumor-stroma ratio in colon cancer: Procedure and recommendations. Virchows Arch. 2018, 473, 405–412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huijbers, A.; Tollenaar, R.A.E.M.; Pelt, G.W.V.; Zeestraten, E.C.M.; Dutton, S.; McConkey, C.C.; Domingo, E.; Smit, V.T.H.B.M.; Midgley, R.; Warren, B.F.; et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: Validation in the VICTOR trial. Ann. Oncol. 2013, 24, 179–185. [Google Scholar] [CrossRef] [PubMed]
- Zhang, T.; Xu, J.; Shen, H.; Dong, W.; Ni, Y.; Du, J. Tumor-stroma ratio is an independent predictor for survival in NSCLC. Int. J. Clin. Exp. Pathol. 2015, 8, 11348–11355. [Google Scholar]
- Chen, Y.; Zhang, L.; Liu, W.; Liu, X. Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer. BioMed Res. Int. 2015, 2015, 589301. [Google Scholar] [CrossRef] [Green Version]
- Liu, J.; Liu, J.; Li, J.; Chen, Y.; Guan, X.; Wu, X.; Hao, C.h.; Sun, Y.; Wang, Y.; Wang, X. Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma. Gynecol. Oncol. 2014, 132, 81–86. [Google Scholar] [CrossRef]
- Vangangelt, K.M.H.; Tollenaar, L.S.A.; van Pelt, G.W.; de Kruijf, E.M.; Dekker, T.J.A.; Kuppen, P.J.K.; Tollenaar, R.A.E.M.; Mesker, W.E. The prognostic value of tumor–stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients. Int. J. Cancer 2018, 143, 3194–3200. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- de Kruijf, E.M.; van Nes, J.G.H.; van de Velde, C.J.H.; Putter, H.; Smit, V.T.H.B.M.; Liefers, G.J.; Kuppen, P.J.K.; Tollenaar, R.A.E.M. Mesker WE. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res. Treat. 2011, 125, 687–696. [Google Scholar] [CrossRef] [PubMed]
- Roeke, T.; Sobral-Leite, M.; Dekker, T.J.A.; Wesseling, J.; Smit, V.T.H.B.M.; Tollenaar, R.A.E.M.; Schmidt, M.K.; Mesker, W.E. The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: A validation study. Breast Cancer Res. Treat. 2017, 166, 435–445. [Google Scholar] [CrossRef]
- Downey, C.L.; Simpkins, S.A.; White, J.; Holliday, D.L.; Jones, J.L.; Jordan, L.B.; Kulka, J.; Pollock, S.; Rajan, S.S.; Thygesen, H.H.; et al. The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer. BJC 2014, 110, 1744–1747. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Panayiotou, H.; Orsi, N.M.; Thygesen, H.H.; Wright, A.I.; Winder, M.; Hutson, R.; Cummings, M. The prognostic significance of tumour-stroma ratio in endometrial carcinoma. BMC Cancer 2015, 15, 955. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ayala, G.; Tuxhorn, J.A.; Wheeler, T.M.; Frolov, A.; Scardino, P.T.; Ohori, M.; Wheeler, M.; Spitler, J.; Rowley, D.R. Reactive Stroma as a Predictor of Biochemical-Free Recurrence in Prostate Cancer. Clin. Cancer Res. 2003, 9, 4792–4801. [Google Scholar] [PubMed]
- Yanagisawa, N.; Li, R.; Rowley, D.; Liu, H.; Kadmon, D.; Miles, B.J.; Wheeler, T.M.; Ayala, G.E. Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum. Pathol. 2008, 39, 282–291. [Google Scholar] [CrossRef] [PubMed]
- Bianconi, F.; Álvarez-Larrán, A.; Fernández, A. Discrimination between tumour epithelium and stroma via perception-based features. Neurocomputing 2015, 154, 119–126. [Google Scholar] [CrossRef]
- Eminaga, O.; Al-Hamad, O.; Boegemann, M.; Breil, B.; Semjonow, A. Combination possibility and deep learning model as clinical decision-aided approach for prostate cancer. Health Inform. J. 2020, 26, 945–962. [Google Scholar] [CrossRef] [Green Version]
- Niazi, M.K.K.; Parwani, A.V.; Gurcan, M.N. Digital pathology and artificial intelligence. Lancet Oncol. 2019, 20, 253–261. [Google Scholar] [CrossRef]
- van Pelt, G.; Tollenaar, R.; Mesker, W. Filling the Gap between Microscopic and Automated Analysis of the Tumor-Stroma Ratio. Ann. Colorectal. Res. 2020, 8, 29–32. [Google Scholar]
- Du, Y.; Zhang, R.; Zargari, A.; Thai, T.C.; Gunderson, C.C.; Moxley, K.M.; Liu, H.; Zheng, B.; Qiu, Y. Classification of Tumor Epithelium and Stroma by Exploiting Image Features Learned by Deep Convolutional Neural Networks. Ann. Biomed. Eng. 2018, 46, 1988–1999. [Google Scholar] [CrossRef]
- Bhargava, H.K.; Leo, P.; Elliott, R.; Janowczyk, A.; Whitney, J.; Gupta, S.; Fu, P.; Yamoah, K.; Khani, F.; Robinson, B.D.; et al. Computationally derived image signature of stromal morphology is prognostic of prostate cancer recurrence following prostatectomy in African American patients. Clin. Cancer Res. 2020, 26, 1915–1923. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hu, Y.; Wu, Q.; Gao, J.; Zhang, Y.; Wang, Y. A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression. BMC Urol. 2019, 19, 67. [Google Scholar] [CrossRef] [PubMed]
- Massoner, P.; Thomm, T.; Mack, B.; Untergasser, G.; Martowicz, A.; Bobowski, K.; Klocker, H.; Gires, O.; Puhr, M. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205. Br. J. Cancer 2014, 111, 955–964. [Google Scholar] [CrossRef] [Green Version]
- Ni, J.; Cozzi, P.J.; Duan, W.; Shigdar, S.; Graham, P.H.; John, K.H.; Li, Y. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev. 2012, 31, 779–791. [Google Scholar] [CrossRef]
- Vangangelt, K.M.H.; Green, A.R.; Heemskerk, I.M.F.; Cohen, D.; van Pelt, G.W.; Sobral-Leite, M.; Schmidt, M.K.; Putter, H.; Rakha, E.A.; Tollenaar, R.A.E.M.; et al. The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. Int. J. Cancer 2020, 146, 2296–2304. [Google Scholar] [CrossRef] [Green Version]
- Su, B.; Gao, L.; Baranowski, C.; Gillard, B.; Wang, J.; Ransom, R.; Ko, H.K.; Gelman, I.H. A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer. PLoS ONE 2014, 9, e101411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mesker, W.E.; Liefers, G.J.; Junggeburt, J.M.; van Pelt, G.W.; Alberici, P.; Kuppen, P.J.; Miranda, N.F.; van Leeuwen, K.A.; Morreau, H.; Szuhai, K.; et al. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol. 2009, 31, 169–178. [Google Scholar] [PubMed]
- Scheer, R.; Baidoshvili, A.; Zoidze, S.; Elferink, M.A.G.; Berkel, A.E.M.; Klaase, J.M.; van Diest, P.J. Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study. World J. Gastrointest. Oncol. 2017, 9, 466–474. [Google Scholar] [CrossRef]
- Xi, K.-X.; Wen, Y.-S.; Zhu, C.-M.; Yu, X.-Y.; Qin, R.-Q.; Zhang, X.-W.; Lin, Y.-B.; Rong, T.-H.; Wang, W.-D.; Chen, Y.-Q.; et al. Tumor-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival. J. Thorac. Dis. 2017, 9, 4017–4026. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eriksen, A.C.; Andersen, J.B.; Lindebjerg, J.; dePont Christensen, R.; Hansen, T.F.; Kjær-Frifeldt, S.; Sørensen, F.B. Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer? Diagn. Pathol. 2018, 13, 20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hansen, T.F.; Kjær-Frifeldt, S.; Lindebjerg, J.; Rafaelsen, S.R.; Jensen, L.H.; Jakobsen, A.; Sørensen, F.B. Tumor–stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. Acta Oncol. 2018, 57, 528–533. [Google Scholar] [CrossRef] [PubMed]
- Stylianou, N.; Lehman, M.L.; Wang, C.; Fard, A.T.; Rockstroh, A.; Fazli, L.; Jovanovic, L.; Ward, M.; Sadowski, M.C.; Kashyap, A.S.; et al. A molecular portrait of epithelial–mesenchymal plasticity in prostate cancer associated with clinical outcome. Oncogene 2019, 38, 913–934. [Google Scholar] [CrossRef] [PubMed]
- Königsberg, R.; Obermayr, E.; Bises, G.; Pfeiler, G.; Gneist, M.; Wrba, F.; de Santis, M.; Zeillinger, R.; Hudec, M.; Dittrich, C. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 2011, 50, 700–710. [Google Scholar] [CrossRef]
- Nastały, P.; Filipska, M.; Morrissey, C.; Elke, E.; Semjonow, A.; Brandt, B.; Pantel, K.; Bednarz-Knoll, N. ALDH1-Positive Intratumoral Stromal Cells Indicate Differentiated Epithelial-Like Phenotype and Good Prognosis in Prostate Cancer. Transl. Res. 2019, 203, 49–56. [Google Scholar] [CrossRef] [PubMed]
- Omari, A.; Nastały, P.; Stoupiec, S.; Omari, A.; Nastały, P.; Stoupiec, S.; Bałabas, A.; Dąbrowska, M.; Bielińska, B.; Huss, S. Somatic Aberrations of BRCA1 Gene are Associated with ALDH1, EGFR, and Tumor Progression in Prostate Cancer. Int. J. Cancer 2019, 144, 607–614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- D’Amico, A.V.; Whittington, R.; Malkowicz, S.B.; Schultz, D.; Blank, K.; Broderick, G.A.; Tomaszewski, J.E.; Renshaw, A.A.; Kaplan, I.; Beard, C.J.; et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280, 969–974. [Google Scholar] [CrossRef] [PubMed]
- Mohler, J.; Bahnson, R.R.; Boston, B.; Busby, J.E.; D’Amico, A.; Eastham, J.A.; Enke, C.A.; George, D.; Horwitz, E.M.; Huben, R.P.; et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J. Natl. Compr. Canc. Netw.. 2010, 8, 162–200. [Google Scholar] [CrossRef]
- Smentoch, J.; Szade, J.; Żaczek, A.J.; Eltze, E.; Semjonow, A.; Brandt, B.; Bednarz-Knoll, N. Low numbers of vascular vessels correlate to progression in Hormone-Naïve prostate carcinomas undergoing radical prostatectomy. Cancers 2019, 11, 1356. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bednarz, N.; Eltze, E.; Semjonow, A.; Rink, M.; Andreas, A.; Mulder, L.; Hannemann, J.; Fisch, M.; Pantel, K.; Weier, H. BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood. Clin. Cancer Res. 2010, 16, 3340–3348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heßling, S. Prognostische Relevanz in Bezug auf die Expression von LOXL2 bei den Verschiedenen Manifestationsformen des Prostatakarzinoms (Prognostic Relevance with Respect to the Expression of LOXL2 in the Different Manifestations of Prostate Cancer). Ph.D. Thesis, University of Münster, Münster, Germany, 2007. [Google Scholar]
- Schmidt, H.; Semjonow, A.; Csiszar, K.; Korsching, E.; Brandt, B.; Eltze, E. Mapping Eines Deletionsintervalls auf 8p21-22 beim Prostatakarzionom mittels Gendosis-PCR (Mapping of a Deletion Interval on 8p21-22 in the Prostate Carcinoma Using Gene-Dose PCR). Verh. Dtsch. Ges. Pathol. 2007, 91, 302–307. [Google Scholar] [PubMed]
- Nastały, P.; Stoupiec, S.; Popęda, M.; Smentoch, J.; Schlomm, T.; Morrissey, C.; Żaczek, A.J.; Beyer, B.; Tennstedt, P.; Graefen, M.; et al. EGFR as a stable marker of prostate cancer dissemination to bones. Br. J. Cancer 2020, 123, 1767–1774. [Google Scholar] [CrossRef] [PubMed]
- Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 2012, 9, 676–682. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruifrok, A.C.; Johnston, D.A. Quantification of histochemical staining by color deconvolution. Anal. Quant. Cytol. Histol. 2001, 23, 291–299. [Google Scholar] [PubMed]
Clinical and Pathological Parameters | Pilot Cohort | Validation Cohort | |||
---|---|---|---|---|---|
Status | n | % | n | % | |
Age (years) | <median (65) | 37 | 52.1 | 102 | 48.8 |
≥median (65) | 34 | 47.9 | 107 | 51.2 | |
Total | 72 | 209 | |||
T status | pT2 | 34 | 52.2 | 95 | 45.4 |
pT3 | 31 | 47.5 | 94 | 45.0 | |
pT4 | 0 | 0.0 | 20 | 9.6 | |
Total | 65 | 209 | |||
N status | pN0 | 62 | 93.9 | 191 | 94.1 |
pN1-2 | 4 | 6.1 | 12 | 5.9 | |
Total | 66 | 203 | |||
Gleason score sum | <7 | 0 | 0.00 | 52 | 24.9 |
7 | 45 | 64.3 | 140 | 67.0 | |
>7 | 25 | 35.7 | 17 | 8.1 | |
Total | 70 | 209 | |||
Preoperative PSA | <10 ng/ml | 46 | 63.9 | 132 | 65.5 |
≥10 ng/ml | 26 | 36.1 | 76 | 36.5 | |
Total | 72 | 205 | |||
d’Amico scale | low risk | 0 | 0.0 | 2 | 1.0 |
intermediate risk | 0 | 0.0 | 46 | 22.3 | |
high/very high risk | 72 | 100.0 | 158 | 76.7 | |
Total | 72 | 206 | |||
Biochemical recurrence | No | 34 | 70.8 | 166 | 79.4 |
Yes | 14 | 29.2 | 43 | 20.6 | |
Total | 48 | 209 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nastały, P.; Smentoch, J.; Popęda, M.; Martini, E.; Maiuri, P.; Żaczek, A.J.; Sowa, M.; Matuszewski, M.; Szade, J.; Kalinowski, L.; et al. Low Tumor-to-Stroma Ratio Reflects Protective Role of Stroma against Prostate Cancer Progression. J. Pers. Med. 2021, 11, 1088. https://doi.org/10.3390/jpm11111088
Nastały P, Smentoch J, Popęda M, Martini E, Maiuri P, Żaczek AJ, Sowa M, Matuszewski M, Szade J, Kalinowski L, et al. Low Tumor-to-Stroma Ratio Reflects Protective Role of Stroma against Prostate Cancer Progression. Journal of Personalized Medicine. 2021; 11(11):1088. https://doi.org/10.3390/jpm11111088
Chicago/Turabian StyleNastały, Paulina, Julia Smentoch, Marta Popęda, Emanuele Martini, Paolo Maiuri, Anna J. Żaczek, Marek Sowa, Marcin Matuszewski, Jolanta Szade, Leszek Kalinowski, and et al. 2021. "Low Tumor-to-Stroma Ratio Reflects Protective Role of Stroma against Prostate Cancer Progression" Journal of Personalized Medicine 11, no. 11: 1088. https://doi.org/10.3390/jpm11111088